Graduate Diploma [Grad.Dip] (Biomedical Art)
Field of Study:
$6,450 /Yr
CSULB Graduate Diploma Biomedical Art is a 3 years Full Time Diploma program. This program is offered On Campus. The first year fees for Graduate Diploma Biomedical Art at CSULB is ₹ 5.73 Lakhs (USD 6450). Earlier in 2023, the Graduate Diploma Biomedical Art Fee was ₹ 13.71 Lakhs (USD 15446). This shows that the academic fees has decreased by ₹ -798754 (USD -8996).
CSULB Graduate Diploma Biomedical Art Total Fees 2025
The tuition fee for Graduate Diploma Biomedical Art at CSULB is USD 6450 per year (₹ 5.73 Lakhs).
The tuition fee for Graduate Diploma Biomedical Art at California State University is as follows:
| Expense Type | Average Cost (INR) | Equivalent (USD) |
|---|---|---|
| Tuition Fee | ₹ 5.73 Lakhs | USD 6450 |
Graduate Diploma Biomedical Art Tuition Fee Trends at CSULB
CSULB Graduate Diploma Biomedical Art Fees for Indian students is ₹ 5.73 Lakhs (USD 6450). This academic fee has remained the same from 2023. Candidates can check the year on year trends in CSULB Fees in the table below.
| Academic Year | Tuition Fees (INR) | Tuition Fees (USD) |
|---|---|---|
| 2024 | ₹ 5.73 Lakhs | USD 6450 |
| 2023 | ₹ 13.71 Lakhs | USD 15446 |
CSULB Graduate Diploma Biomedical Art Application Link
CSULB Graduate Diploma Biomedical Art Application Link; Apply Here
Also Check:Tuition Fees
| Year | 1st Year Fees |
|---|---|
| Tuition Fees | $6450 |
Previous Year Tuition Fees
| Year | 1st Year Fees |
|---|---|
| 2023 | $15446 |
Key Resources for Your Study Abroad Journey
Scholarship Grants & Financial Aids
| Name | Scholarship Per Student | Level of Study | Type | |
|---|---|---|---|---|
| Comindware Scholarship | Scholarship per student$ 4,000/Yr$4,000 | Level Of StudyApprenticeship | TypeMerit-Based | |
| Forktip Women’s- Innovation Scholarship | Scholarship per studentVariable Amount | Level Of StudyBachelor | TypeCollege-Specific | |
| BL Mandhana Scholarships | Scholarship per student$ 10,000/Yr$10,000 | Level Of StudyBachelor | TypeMerit-Based |
















Comments